<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04770831</url>
  </required_header>
  <id_info>
    <org_study_id>LCI-PED-NEU-MIBG-001</org_study_id>
    <secondary_id>00047671</secondary_id>
    <nct_id>NCT04770831</nct_id>
  </id_info>
  <brief_title>Patients Who Receive 131 I-MIBG</brief_title>
  <official_title>An Observational Study of Patients With Recurrent Progressive or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma Who Receive 131 I- MIBG</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atrium Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atrium Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is for patients who have have neuroblastoma, pheochromocytoma, or paraganglioma&#xD;
      that has come back (relapsed) after treatment or has not gotten better (refractory) with&#xD;
      standard treatment. The purpose of this study is to evaluate quality of life and response&#xD;
      rate to 131 I-MIBG treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational, single institution study designed to determine the benefit of&#xD;
      131I-MIBG therapy in subjects with refractory, relapsed or progressive neuroblastoma,&#xD;
      malignant pheochromocytoma or paraganglioma, or other neuroendocrine tumors. Response rate,&#xD;
      time to progression, and quality of life changes will be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>For up to 2 years after treatment with 131 I-MIBG</time_frame>
    <description>To assess health related quality of life prior to, during and after therapy with 131 I-MIBG. For subject's â‰¥8 years of age, their patient reported Peds QL will be compared to their caregiver's perspective.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>From on study date to date of progression or death, for up to 5 years</time_frame>
    <description>To assess progression free survival (PFS) to 131I-MIBG therapy for subjects with refractory, relapsed or progressive neuroblastoma, malignant pheochromocytoma or paraganglioma, or other neuroendocrine tumors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>From on study date to off study date, for up to 5 years</time_frame>
    <description>To evaluate disease control rate to 131I-MIBG treatment in subjects with refractory, relapsed or progressive neuroblastoma or other neuroendocrine tumors (not limited to but including malignant pheochromocytoma or paraganglioma).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Brain and Nervous System</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <description>QOL following MIBG</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with refractory, relapsed or progressive neuroblastoma, malignant pheochromocytoma&#xD;
        or paraganglioma, or other neuroendocrine tumors will be recruited at Levine Cancer&#xD;
        Institute (LCI), Torrence E. Hemby Jr. Pediatric Hematology &amp; Oncology Center, or Atrium&#xD;
        Health Levine Children's Hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Subject must meet all of the following applicable inclusion criteria to participate in this&#xD;
        study:&#xD;
&#xD;
          1. Written informed consent, and assent where applicable, and HIPAA authorization for&#xD;
             release of personal health information. NOTE: HIPAA authorization may be included in&#xD;
             the informed consent or obtained separately.&#xD;
&#xD;
          2. Age greater than or equal to 1 years and less than or equal to 30 years at the time of&#xD;
             therapy.&#xD;
&#xD;
          3. Subject is scheduled to receive 131 I-MIBG therapy.&#xD;
&#xD;
          4. Diagnosis of refractory, progressive or relapsed Neuroblastoma, Malignant&#xD;
             Paraganglioma, Malignant Pheochromocytoma or other Neuroendocrine Tumors.&#xD;
&#xD;
          5. As determined by the enrolling physician, ability of the subject and parent/caregiver&#xD;
             to understand and comply with study procedures for the entire length of the study.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Subjects meeting the criteria below may not participate in the study:&#xD;
&#xD;
        1. Prior enrollment on LCI-PED-NEU-MIBG-001 trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jontyce Green, RN</last_name>
    <phone>980-442-2356</phone>
    <email>jontyce.green@atriumhealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Javier Oesterheld, MD</last_name>
    <email>javier.oesterheld@atriumhealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Devika Srivastava, RN</last_name>
      <phone>980-442-2354</phone>
      <email>devika.srivastava@atriumhealth.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 16, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Atrium Health</investigator_affiliation>
    <investigator_full_name>Javier Oesterheld</investigator_full_name>
    <investigator_title>Javier Oesterheld MD</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

